BR112012029656A2 - composições para uso no tratamento ou diagnóstico de disturbios ósseos e/ou distúrbios cardiovasculares - Google Patents
composições para uso no tratamento ou diagnóstico de disturbios ósseos e/ou distúrbios cardiovascularesInfo
- Publication number
- BR112012029656A2 BR112012029656A2 BR112012029656A BR112012029656A BR112012029656A2 BR 112012029656 A2 BR112012029656 A2 BR 112012029656A2 BR 112012029656 A BR112012029656 A BR 112012029656A BR 112012029656 A BR112012029656 A BR 112012029656A BR 112012029656 A2 BR112012029656 A2 BR 112012029656A2
- Authority
- BR
- Brazil
- Prior art keywords
- disorders
- bone
- compounds
- compositions
- polynucleotide
- Prior art date
Links
- 208000024172 Cardiovascular disease Diseases 0.000 title abstract 6
- 208000020084 Bone disease Diseases 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000003745 diagnosis Methods 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 6
- 108091033319 polynucleotide Proteins 0.000 abstract 4
- 102000040430 polynucleotide Human genes 0.000 abstract 4
- 239000002157 polynucleotide Substances 0.000 abstract 4
- 230000003247 decreasing effect Effects 0.000 abstract 3
- 108091060585 Mir-31 Proteins 0.000 abstract 2
- 210000000988 bone and bone Anatomy 0.000 abstract 2
- 238000002405 diagnostic procedure Methods 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000010392 Bone Fractures Diseases 0.000 abstract 1
- 206010005949 Bone cancer Diseases 0.000 abstract 1
- 208000018084 Bone neoplasm Diseases 0.000 abstract 1
- 102100021262 Frizzled-3 Human genes 0.000 abstract 1
- 101710140944 Frizzled-3 Proteins 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010061216 Infarction Diseases 0.000 abstract 1
- 208000029725 Metabolic bone disease Diseases 0.000 abstract 1
- 206010049088 Osteopenia Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 201000004810 Vascular dementia Diseases 0.000 abstract 1
- 206010057469 Vascular stenosis Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000013632 homeostatic process Effects 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 230000007574 infarction Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Dispersion Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10163604 | 2010-05-21 | ||
| PCT/EP2011/058379 WO2011144761A1 (en) | 2010-05-21 | 2011-05-23 | Compositions for use in treating or diagnosing bone disorders and/or cardiovascular disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012029656A2 true BR112012029656A2 (pt) | 2016-12-13 |
Family
ID=44537805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012029656A BR112012029656A2 (pt) | 2010-05-21 | 2011-05-23 | composições para uso no tratamento ou diagnóstico de disturbios ósseos e/ou distúrbios cardiovasculares |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20130108687A1 (https=) |
| EP (1) | EP2571988B1 (https=) |
| JP (1) | JP5894581B2 (https=) |
| CN (1) | CN103210085B (https=) |
| BR (1) | BR112012029656A2 (https=) |
| CA (1) | CA2800018C (https=) |
| WO (1) | WO2011144761A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103316342A (zh) * | 2013-02-28 | 2013-09-25 | 中国人民解放军沈阳军区总医院 | MiR-31抑制剂用于抑制血管损伤后再狭窄的用途 |
| GB201309882D0 (en) * | 2013-06-03 | 2013-07-17 | Isis Innovation | Prevention and treatment of atrial fibrillation |
| US20160120805A1 (en) * | 2013-06-05 | 2016-05-05 | The Trustees Of Columbia University In The City Of New York | Exosomes for orofacial diagnostics and therapeutics |
| CN103627705B (zh) * | 2013-10-28 | 2016-02-24 | 南京医科大学 | 与膀胱癌相关的piRNA生物标志物及其应用 |
| BR112016028958A2 (pt) * | 2014-06-13 | 2017-10-31 | Univ Wien Bodenkultur | método in vitro para diagnóstico de osteoporose ou determinação do risco de fraturas osteoporóticas ou monitoramento do tratamento em um indivíduo compreendendo as etapas de coleta de amostra de sangue, de medição do nível de micrornas e de comparação do nível de mirnas com o nível da amostra de referência e composição para tratamento |
| US10517888B2 (en) | 2014-12-08 | 2019-12-31 | Thomas Jefferson University | Treatment and prevention of thrombosis using an anti-miR |
| JP6694240B2 (ja) * | 2015-01-30 | 2020-05-13 | ロート製薬株式会社 | 細胞の品質を評価する方法、及び細胞の品質判定キット |
| CN107176976B (zh) * | 2016-03-11 | 2020-02-14 | 上海交通大学医学院 | 微小rna31前体编码多肽在制备免疫调节药物中的应用 |
| CN107151695B (zh) * | 2016-12-08 | 2021-11-09 | 青岛大学 | 用于检测急性心肌缺血疾病的piRNA组合及其检测方法和应用 |
| CN110129429A (zh) * | 2019-05-22 | 2019-08-16 | 昌乐县人民医院 | 核酸分子在制备诊断骨科疾病的产品中的应用 |
| CN110055256A (zh) * | 2019-05-31 | 2019-07-26 | 固安博健生物技术有限公司 | Loc105376287作为诊断男性骨质疏松症的分子标志物的用途 |
| CN110184270A (zh) * | 2019-05-31 | 2019-08-30 | 固安博健生物技术有限公司 | 非编码rna作为男性骨质疏松症的诊断标志物 |
| CN110951869B (zh) * | 2020-01-02 | 2021-06-18 | 北京市创伤骨科研究所 | 骨质疏松诊治用生物标志物 |
| CN111118139B (zh) * | 2020-01-13 | 2021-06-18 | 北京市创伤骨科研究所 | 一种骨质疏松的分子靶标及其应用 |
| CN111599476B (zh) * | 2020-05-15 | 2023-08-11 | 中南大学湘雅医院 | 一种高血压的预测模型及其建立方法以及用于预测高血压的生物标记物 |
| CN112746101B (zh) * | 2020-12-25 | 2023-02-28 | 深圳市人民医院 | 一种骨质疏松诊断标志物及促进骨质疏松骨再生的核酸药物 |
| CN114426950B (zh) * | 2022-01-25 | 2023-08-04 | 北京大学口腔医学院 | 一种高成骨成血管的血清外泌体及其制备方法和应用 |
| WO2025184665A1 (en) * | 2024-03-01 | 2025-09-04 | Immorta Bio, Inc. | Senescence vaccine |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4711955A (en) | 1981-04-17 | 1987-12-08 | Yale University | Modified nucleotides and methods of preparing and using same |
| CA1223831A (en) | 1982-06-23 | 1987-07-07 | Dean Engelhardt | Modified nucleotides, methods of preparing and utilizing and compositions containing the same |
| US5792608A (en) | 1991-12-12 | 1998-08-11 | Gilead Sciences, Inc. | Nuclease stable and binding competent oligomers and methods for their use |
| US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
| US5998424A (en) | 1997-06-19 | 1999-12-07 | Dupont Pharmaceuticals Company | Inhibitors of factor Xa with a neutral P1 specificity group |
| EP0943684A3 (en) * | 1998-03-10 | 2002-01-23 | Smithkline Beecham Plc | Frizzled-like polypeptides and polynucleotides |
| US7655785B1 (en) * | 2002-11-14 | 2010-02-02 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof |
| CA2507496C (en) * | 2002-12-05 | 2014-11-04 | John D. Shaughnessy | Molecular determinants of myeloma bone disease and uses thereof |
| US7135493B2 (en) | 2003-01-13 | 2006-11-14 | Astellas Pharma Inc. | HDAC inhibitor |
| AR043507A1 (es) | 2003-03-14 | 2005-08-03 | Lundbeck & Co As H | Derivados de anilina sustituidos y composiciones farmaceuticas |
| US7683036B2 (en) * | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
| EP1723162A4 (en) * | 2004-02-13 | 2010-05-05 | Univ Rockefeller | ANTI-microRNA oligonucleotide molecules |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| EP2007888A2 (en) * | 2006-04-03 | 2008-12-31 | Santaris Pharma A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
| EP2051964A4 (en) | 2006-07-28 | 2012-03-07 | Univ Connecticut | INHIBITORS OF FATTY ACID AMIDHYDROLASE |
| US7993831B2 (en) * | 2007-09-14 | 2011-08-09 | Asuragen, Inc. | Methods of normalization in microRNA detection assays |
| EP2414830A2 (en) | 2009-03-31 | 2012-02-08 | Robert Zimmermann | Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor |
| US20130210883A1 (en) | 2010-05-21 | 2013-08-15 | Johannes Grillari | Lipase inhibitors |
-
2011
- 2011-05-23 JP JP2013511636A patent/JP5894581B2/ja not_active Expired - Fee Related
- 2011-05-23 EP EP11727134.6A patent/EP2571988B1/en active Active
- 2011-05-23 BR BR112012029656A patent/BR112012029656A2/pt not_active Application Discontinuation
- 2011-05-23 CA CA2800018A patent/CA2800018C/en active Active
- 2011-05-23 CN CN201180034123.1A patent/CN103210085B/zh not_active Expired - Fee Related
- 2011-05-23 US US13/699,272 patent/US20130108687A1/en not_active Abandoned
- 2011-05-23 WO PCT/EP2011/058379 patent/WO2011144761A1/en not_active Ceased
-
2013
- 2013-12-02 US US14/094,772 patent/US9150855B2/en not_active Expired - Fee Related
-
2014
- 2014-12-05 US US14/561,585 patent/US9212362B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP5894581B2 (ja) | 2016-03-30 |
| CN103210085B (zh) | 2018-09-25 |
| EP2571988A1 (en) | 2013-03-27 |
| US20150119450A1 (en) | 2015-04-30 |
| CA2800018A1 (en) | 2011-11-24 |
| WO2011144761A1 (en) | 2011-11-24 |
| CN103210085A (zh) | 2013-07-17 |
| JP2013534908A (ja) | 2013-09-09 |
| US9150855B2 (en) | 2015-10-06 |
| EP2571988B1 (en) | 2019-11-20 |
| CA2800018C (en) | 2021-09-28 |
| US20140162265A1 (en) | 2014-06-12 |
| US9212362B2 (en) | 2015-12-15 |
| US20130108687A1 (en) | 2013-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012029656A2 (pt) | composições para uso no tratamento ou diagnóstico de disturbios ósseos e/ou distúrbios cardiovasculares | |
| Zhou et al. | Multiple functions of autophagy in vascular calcification | |
| BR112012010766A2 (pt) | composições e métodos de tratamento da colite e de outras doenças instestinais | |
| DK2364983T3 (da) | Nyt tricyklisk derivat eller farmaceutisk acceptable salte deraf, fremgangsmåde til fremstilling deraf og farmaceutisk sammensætning indeholdende disse | |
| BR112012012947B8 (pt) | sal de hemitartarato e composição farmacêutica compreendendo o mesmo | |
| BRPI0713446B8 (pt) | compostos inibidores de prolil hidroxilase, composição farmacêutica compreendendo os mesmos, usos terapêuticos destes e processo para preparar a dita composição | |
| CL2009001151A1 (es) | Compuestos derivados de acidos carbociclicos aliciclicos de benzomorfanos, procedimiento de preparacion, composicion farmaceutica, utiles para tratar enfermedades influenciadas por la inhibicion de la enzima 11beta-hidroxiesteroide deshidrogenasa, como trastornos metabolicos. | |
| WO2009151598A8 (en) | Diazacarbazoles and methods of use | |
| MX350761B (es) | Inhibidores de isoindolinona de fosfatidilinositol 3-cinasa. | |
| BRPI1015568B8 (pt) | derivados de imidazolidin-2-ona 1,3-dissubstituídos como inibidores de cyp 17, seus usos, e composição farmacêutica | |
| BRPI0818533B8 (pt) | composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto | |
| BR112014004504A2 (pt) | "composto como inibidor de c-kit cinase, seu uso, composição farmacêutica, e medicamento para o tratamento de uma doença mediada por uma cinase" | |
| EA201000341A1 (ru) | 2-анилинопурин-8-оны в качестве ингибиторов ttk/mps1 для лечения пролиферативных нарушений | |
| BRPI0911243B8 (pt) | derivados de benzofurano, benzotiofeno, benzotiazol, e composição farmacêutica | |
| NO20081211L (no) | Xantinderivater som selektive HM74A agonister | |
| BR112015012454A8 (pt) | compostos inibidores de atr quinase, seu uso, composição farmacêutica compreendendo os mesmos, seus intermediários e método de preparação | |
| SG178986A1 (en) | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use | |
| DK2358717T3 (da) | Aminotetrahydropyraner som dipeptidylpeptidase-iv-inhibitorer tilbehandling eller forebyggelse af diabetes | |
| ME01285A (me) | Derivati dioksa-bicikl0[3.2.1]oktan-2,3,4-triola | |
| BRPI0716069A2 (pt) | composto, composiÇço farmacÊutica, e, mÉtodo para tratar um distérbio | |
| BR112018071602A2 (pt) | compostos de imidazopiridina substituídos como inibidores da indolamina 2,3-dioxigenase e/ou triptofano-2,3-dioxigenase | |
| CL2008003093A1 (es) | Compuestos derivados de 6-aril/heteroalquiloxi benzotiazol y bencimidazol; procedimiento de preparacion; composicion farmaceutica, y uso para el tratamiento o la prevencion de trastornos de los vasos sanguineos, alergias, asma, trombosis, artritis reumatoide y cancer, entre otras. | |
| CU20130063A7 (es) | Proceso de producción de depsipéptidos cíclicos | |
| BRPI0905687A8 (pt) | composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto | |
| HK1217944A1 (zh) | 醛糖還原酶抑制劑和其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |